Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNC-077 in Advanced Gastrointestinal and Solid Tumors
NCT06755242Phase 1Not yet recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jan 2025
- Primary completion
- Jun 2027
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Multispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GNC-077 in gastrointestinal tumor and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 2 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
GNC-077
03
Conditions
gastrointestinal tumorsolid tumor
Beyond the preview
Go deeper on NCT06755242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06755242.